GENMAB A/S/S (OTCMKTS:GMXAY – Get Free Report) fell 6.5% during trading on Thursday . The stock traded as low as $19.89 and last traded at $20.23. 1,838,334 shares traded hands during mid-day trading, an increase of 3,686% from the average session volume of 48,553 shares. The stock had previously closed at $21.64.
GENMAB A/S/S Stock Down 6.5 %
The firm’s 50 day simple moving average is $21.23 and its 200 day simple moving average is $24.11.
About GENMAB A/S/S
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Further Reading
- Five stocks we like better than GENMAB A/S/S
- Stock Splits, Do They Really Impact Investors?
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a Dividend King?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for GENMAB A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.
